• +1-646-491-9876
    • +91-20-67278686

    Search

    Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017

    Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017

    • Report Code ID: RW0001767503
    • Category Pharmaceuticals
    • No. of Pages 95
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017, provides an overview of the Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline landscape.

    Neuromyelitis optica (NMO) , also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 3, 4 and 8 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

    Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Neuromyelitis Optica (Devic's Syndrome) - Overview
    Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
    2-BBB Medicines BV
    Alexion Pharmaceuticals Inc
    Apellis Pharmaceuticals Inc
    Biogen Inc
    Bionure Farma SL
    Chugai Pharmaceutical Co Ltd
    Clene Nanomedicine Inc
    HanAll Biopharma Co Ltd
    Karus Therapeutics Ltd
    LFB SA
    Marathon Pharmaceuticals LLC
    MedImmune LLC
    Opexa Therapeutics Inc
    Shire Plc
    Neuromyelitis Optica (Devic's Syndrome) - Drug Profiles
    2B-3201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ANV-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APL-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BN-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cladribine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CNMAU-8 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-15107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HL-161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    inebilizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KA-1463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OPX-212 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SA-237 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-623 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Neuromyelitis Optica - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ublituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects
    Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones
    Featured News & Press Releases
    Sep 16, 2016: TG Therapeutics Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    Aug 31, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
    Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
    Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
    Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
    May 08, 2015: Initiation Of Phase I Clinical Program
    Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
    Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
    Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund
    Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
    Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
    Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
    Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
    Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by 2-BBB Medicines BV, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma SL, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Clene Nanomedicine Inc, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Karus Therapeutics Ltd, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB SA, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune LLC, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics Inc, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H1 2017
    Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    2-BBB Medicines BV
    Alexion Pharmaceuticals Inc
    Apellis Pharmaceuticals Inc
    Biogen Inc
    Bionure Farma SL
    Chugai Pharmaceutical Co Ltd
    Clene Nanomedicine Inc
    HanAll Biopharma Co Ltd
    Karus Therapeutics Ltd
    LFB SA
    Marathon Pharmaceuticals LLC
    MedImmune LLC
    Opexa Therapeutics Inc
    Shire Plc

    Request for Sample

    Report Url http://www.reportsweb.com//neuromyelitis-optica-devics-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//neuromyelitis-optica-devics-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//neuromyelitis-optica-devics-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments